Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseaseThis drugclass are thebackbone ofHR+ diseaseThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Used asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredfrequencyof GnRHagonistsPreferredregimen forHR+ diseasefor frail/elderlypatientsThis treatmentmodality isalwayscombined withlumpectomysurgeryBased onOncotype DX,a score of 35will receivethis treatmentI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancer1%Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe onlysteroidalaromataseinhibitor in itsdrug classThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseaseThis drugclass are thebackbone ofHR+ diseaseThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Used asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredfrequencyof GnRHagonistsPreferredregimen forHR+ diseasefor frail/elderlypatientsThis treatmentmodality isalwayscombined withlumpectomysurgeryBased onOncotype DX,a score of 35will receivethis treatmentI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancer1%Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe onlysteroidalaromataseinhibitor in itsdrug classThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate 

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Patients with HER2+ disease continue targeted therapy for this duration
  2. This agent can be added to LN+ HER2+ disease given with trastuzumab
  3. Duration of time patients will take abemaciclib in early stage disease
  4. This drug class are the backbone of HR+ disease
  5. This agent should be initiated with neratinib for the first 8 weeks
  6. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  7. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  8. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  9. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  10. Preferred frequency of GnRH agonists
  11. Preferred regimen for HR+ disease for frail/elderly patients
  12. This treatment modality is always combined with lumpectomy surgery
  13. Based on Oncotype DX, a score of 35 will receive this treatment
  14. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  15. This should be monitored routinely every 3-4 months while receiving trastuzumab
  16. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  17. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  18. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  19. 1%
  20. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  21. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  22. This agent can cause endometrial cancer, but has bone density protective effect
  23. The only steroidal aromatase inhibitor in its drug class
  24. This subtype of breast cancer has the lowest relative 5-year survival rate